The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
NCT00726934 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 149
Last updated 2017-02-08
Summary
The purpose of this study is to determine if FDA approved food safety guidelines are equivalent to a low bacterial diet (the neutropenic diet) with respect to the acquisition of infections during neutropenia in a sample of pediatric cancer patients.
Conditions
- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- Non-Hodgkins Lymphoma
- Sarcoma
- Neuroblastoma
Interventions
- OTHER
-
Food Safety Guidelines
Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.
- OTHER
-
Neutropenic Diet
The Neutropenic Diet Guideline includes all information contained in the FDA Food Safety Guidelines with the addition of the following recommendations: 1. Avoid raw vegetables and fruit (Oranges and bananas are okay.) 2. Avoid take-out foods and fast foods and fountain drinks. 3. Avoid aged cheese (blue, Roquefort, Brie). 4. Cook all produce to well done. Eggs must be hard-boiled. 5. Avoid deli meats. 6. No raw nuts, nuts roasted in shell, or freshly ground nut butters from a health food store. 7. No well water 8. No yogurt
Sponsors & Collaborators
-
Indiana University
lead OTHER
Principal Investigators
-
Karen Moody, MD, MS · Indiana University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Year
- Max Age
- 30 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-09-30
- Primary Completion
- 2017-01-31
- Completion
- 2017-01-31
Countries
- United States
Study Locations
More Related Trials
-
Prophylaxis of Febrile Neutropenia With Lactoferrin in Oncohematologic Children Undergoing Induction Chemotherapy
NCT07113314 ·Status: COMPLETED ·Phase: NA
-
Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients-Pilot Study
NCT02417168 ·Status: TERMINATED
-
Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia
NCT03449693 ·Status: UNKNOWN ·Phase: PHASE2
-
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
NCT02996617 ·Status: UNKNOWN ·Phase: PHASE4
-
Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy
NCT00003739 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia
NCT02761460 ·Status: UNKNOWN ·Phase: PHASE3
-
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
NCT00503854 ·Status: COMPLETED
-
Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy
NCT04477616 ·Status: COMPLETED ·Phase: PHASE2
-
Various G-CSF Regimens to Prevent Infection During Chemotherapy
NCT00536081 ·Status: COMPLETED ·Phase: PHASE3
-
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
NCT03846414 ·Status: UNKNOWN
-
Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study
NCT01763398 ·Status: COMPLETED
-
Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program
NCT04557709 ·Status: WITHDRAWN
-
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
NCT04009941 ·Status: COMPLETED ·Phase: PHASE4
-
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
NCT06711523 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
NCT04101760 ·Status: UNKNOWN ·Phase: PHASE3
-
Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia
NCT02536599 ·Status: UNKNOWN
-
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
NCT03618810 ·Status: UNKNOWN
-
Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.
NCT07204522 ·Status: RECRUITING
-
Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia
NCT01450241 ·Status: WITHDRAWN ·Phase: NA
-
The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy
NCT02905916 ·Status: UNKNOWN ·Phase: PHASE4
-
Correlation of Timing of Pegfilgrastim Administration and PIBP.
NCT05841186 ·Status: RECRUITING ·Phase: NA
-
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
NCT06510868 ·Status: RECRUITING
-
Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
NCT03823950 ·Status: UNKNOWN ·Phase: PHASE4
-
Continuous Versus Bolus Administration of G-CSF in Children With Cancer
NCT06145321 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy
NCT04081753 ·Status: COMPLETED ·Phase: NA